Onkologie. 2022:16(3):130-133 | DOI: 10.36290/xon.2022.026

Immunotherapy for the treatment of metastatic uveal melanoma

Ján Podhorec, Radek Lakomý, Alexandr Poprach, Igor Kiss
Klinika komplexní onkologické péče, LF MU a MOÚ Brno

Uveal melanoma is the most common ocular malignancy. Despite its common origin in melanocytes, it differs fundamentally from cutaneous melanoma in its biological properties. Metastatic disease has a poor prognosis. It is a chemoresistant disease and the effect of immunotherapy, which marked a breakthrough in the treatment of cutaneous melanoma, is unsatisfactory in uveal melanoma. A clear shift in treatment is tebentafusp, which belongs to the group immTAC (immuno-mobilizing monoclonal TCR against cancer). Tebentafusp was the first drug to demonstrate prolongation of overall survival in a recently published phase III study. The possibilities and benefits of immunotherapy in the treatment of metastatic uveal melanoma are presented in this review article.

Keywords: uveal melanoma, immunotherapy, tebentafusp, nivolumab, ipilimumab, pembrolizumab.

Published: May 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Podhorec J, Lakomý R, Poprach A, Kiss I. Immunotherapy for the treatment of metastatic uveal melanoma. Onkologie. 2022;16(3):130-133. doi: 10.36290/xon.2022.026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mallone S, De Vries E, Guzzo M, et al. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur J Cancer Oxf Engl 1990. 2012;48(8):1167-1175. Go to original source... Go to PubMed...
    2. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye Lond Engl. 2017;31(2):241-257. Go to original source... Go to PubMed...
    3. Amaro A, Gangemi R, Piaggio F, et al. The biology of uveal melanoma. Cancer Metastasis Rev. 2017;36(1):109-140. Go to original source... Go to PubMed...
    4. Javed A, Arguello D, Johnston C, et al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 2017;9(16):1323-1330. Go to original source... Go to PubMed...
    5. Johansson P, Aoude LG, Wadt K, et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget. 2016;7(4):4624-4631. Go to original source... Go to PubMed...
    6. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599-602. Go to original source... Go to PubMed...
    7. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191-2199. Go to original source... Go to PubMed...
    8. Harbour JW, Onken MD, Roberson EDO, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410-1413. Go to original source... Go to PubMed...
    9. Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet Lond Engl. 1996;347(9010):1222-1225. Go to original source... Go to PubMed...
    10. Kuk D, Shoushtari AN, Barker CA, et al. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. The Oncologist. 2016;21(7):848-854. Go to original source... Go to PubMed...
    11. Rowcroft A, Loveday BPT, Thomson BNJ, et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB. 2020;22(4):497-505. Go to original source... Go to PubMed...
    12. Guidelines Detail [Internet]. NCCN. c2022. [cited 2022 Feb 27]. Available from: https://www.nccn.org/guidelines/guidelines-detail.
    13. Další literatura u autora a na www.onkologiecs.cz
    14. Steeb T, Wessely A, Ruzicka T, et al. How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. Eur J Cancer Oxf Engl 1990. 2018;103:41-51. Go to original source... Go to PubMed...
    15. Array Biopharma, now a wholly owned subsidiary of Pfizer. A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma [Internet]. clinicaltrials.gov; c2020. [cited 2022 Feb 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01801358.
    16. Maio M, Danielli R, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(11):2911-2915. Go to original source... Go to PubMed...
    17. Luke JJ, Callahan MK, Postow MA, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013;119(20):3687-3695. Go to original source... Go to PubMed...
    18. Deo MA. Long-term survival benefit from ipilimumab treatment in metastatic uveal melanoma patients. J Clin Oncol. 2014;32(15_suppl):3060-3060. Go to original source...
    19. Zimmer L, Vaubel J, Mohr P, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PloS One. 2015;10(3):e0118564. Go to original source... Go to PubMed...
    20. Rozeman EA, Prevoo W, Meier MAJ, et al. Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). Melanoma. 2020; 30(3):252-260. Go to original source... Go to PubMed...
    21. Kottschade LA, McWilliams RR, Markovic SN, et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016;26(3):300-303. Go to original source... Go to PubMed...
    22. Johnson DB, Bao R, Ancell KK, et al. Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis. J Natl Compr Cancer Netw JNCCN. 2019;17(2):114-117. Go to original source... Go to PubMed...
    23. Rossi E, Pagliara MM, Orteschi D, et al. Pembrolizumab as first-line treatment for metastatic uveal melanoma. Cancer Immunol Immunother CII. 2019;68(7):1179-1185. Go to original source... Go to PubMed...
    24. Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344-3353. Go to original source... Go to PubMed...
    25. Namikawa K, Takahashi A, Mori T, et al. Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study. Melanoma Res. 2020;30(1):76-84. Go to original source... Go to PubMed...
    26. Tacar SY, Selcukbiricik F, Yilmaz M, et al. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021;31(5):449-455. Go to original source... Go to PubMed...
    27. Heppt MV, Amaral T, Kähler KC, et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer. 2019;7(1):299. Go to original source... Go to PubMed...
    28. Najjar YG, Navrazhina K, Ding F, et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020;8(1):e000331. Go to original source... Go to PubMed...
    29. Pelster MS, Gruschkus SK, Bassett R, et al. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(6):599-607. Go to original source... Go to PubMed...
    30. Piulats JM, Espinosa E, de la Cruz Merino L, et al. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(6):586-598. Go to original source... Go to PubMed...
    31. Lowe KL, Cole D, Kenefeck R, et al. Novel TCR-based biologics: mobilising T cells to warm "cold" tumours. Cancer Treat Rev. 2019;77:35-43. Go to original source... Go to PubMed...
    32. Damato BE, Dukes J, Goodall H, et al. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers. 2019;11(7):E971. Go to original source... Go to PubMed...
    33. Middleton MR, McAlpine C, Woodcock VK, et al. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clin Cancer Res. 2020;26(22):5869-5878. Go to original source... Go to PubMed...
    34. Sacco JJ, Carvajal R, Butler MO, et al. 64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM). Ann Oncol. 2020;31:S1442-1443. Go to original source...
    35. Nathan P, Hassel JC, Rutkowski P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021;385(13):1196-1206. Go to original source... Go to PubMed...
    36. Chandran SS, Somerville RPT, Yang JC, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017;18(6):792-802. Go to original source... Go to PubMed...
    37. Gezgin G, Luk SJ, Cao J, et al. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. JAMA Ophthalmol. 2017;135(6):541-549. Go to original source... Go to PubMed...
    38. Ny L, Jespersen H, Karlsson J, et al. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. 2021;12(1):5155.
    39. Tong TML, van der Kooij MK, Speetjens FM, et al. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial. Trials. 2022;23(1):137. Go to original source... Go to PubMed...
    40. Durante MA, Rodriguez DA, Kurtenbach S, et al. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat Commun. 2020;11(1):496. Go to original source... Go to PubMed...
    41. Qin Y, Bollin K, de Macedo MP, et al. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. J Immunother Cancer. 2020;8(2):e000960. Go to original source... Go to PubMed...
    42. Rodrigues M, Mobuchon L, Houy A, et al. Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. Nat Commun. 2018;9(1):1866. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.